FibroGen (FGEN) PT Lowered to $55 at Stifel

April 7, 2021 7:49 AM EDT
Get Alerts FGEN Hot Sheet
Price: $26.06 +3.62%

Rating Summary:
    5 Buy, 8 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 12 | Down: 7 | New: 31
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Annabel Samimy lowered the price target on FibroGen (NASDAQ: FGEN) to $55.00 (from $70.00) while maintaining a Buy rating.

The analyst commented, "FGEN’s clarification of a different Roxadustat cardiovascular safety analysis is another unpleasant surprise, but it is not clear that it changes the ultimate approvability of Roxa. Importantly, Roxa remains comparable to placebo in non-dialysis and to EPO in dialysis-dependent patients. That said, the claims regarding Roxa’s reduced risk (or superiority) of MACE+ in dialysis and MACE/MACE+ in incident-dialysis compared to EPO, which were communicated to the medical and investment community, are no longer valid. We expect this change to hold more weight for the FDA in terms of labeling, than for receptivity of Roxa by physicians. FGEN now has an official AdCom date of 7/15, and we continue to believe that Roxa will be approved given its comparable efficacy, clinical benefits, and safety. However, we have changed the probability weightings of our label-associated Roxa launch curves, removing an expectation for a BBW-free label and bringing our TP to $55."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel, AdCom, FDA